SCHEMBL6097169

SCHEMBL6097169

CCOC(=O)CCC(=O)NC/C=C/c1ccccc1Nc1ccc(C(=O)c2ccccc2C)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.58
MAPK13 O15264 13/20 0.58
MAPK12 P53778 13/20 0.58
MAPK11 Q15759 13/20 0.58
KDM1A O60341 1/20 0.37
MAOB P27338 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
METTL3 Q86U44 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097171 1.00 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11KDM1A
SCHEMBL6095001 0.90 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11L3MBTL1
SCHEMBL6094992 0.90 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11L3MBTL1
SCHEMBL6097149 0.89 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL6097138 0.89 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL6098328 0.88 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL6098325 0.88 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL6095469 0.84 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL6095477 0.84 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL6812883 0.83 MAPK14 (0.76) MAPK14MAPK13MAPK12MAPK11KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US claimed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US claimed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF MAPK14 1972/4885MAPK13 2918/4885MAPK12 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.